ARK Genomic Revolution ETF(ARKG)
AI Look-Through Summary
AI GeneratedThe ARK Genomic Revolution ETF holds a significant portion of its assets in non-traditional healthcare companies, with only about 41% allocated to traditional healthcare sectors. This allocation skews the fund's exposure towards smaller and more innovative players, which may be driving the higher valuation multiples observed in the weighted P/E and P/B metrics.
The top holdings exhibit a high degree of concentration, with the top five names accounting for over 35% of the portfolio. The presence of large-cap pharmaceutical companies like LLY is notable, but their weightings are relatively small compared to the smaller-cap innovators that dominate the fund's composition. As such, investors may want to consider how this concentrated exposure to high-growth, high-multiple stocks would perform in a market environment where valuations come under pressure or growth rates slow.
Generated by Qwen-32B from constituent-level data. Not investment advice. Updated: 2026-07-14 09:46:39.874146+00
🔍 Theme Alignment Audit
AI GeneratedPurity: 78/100The ARK Genomic Revolution ETF demonstrates a strong nominal alignment with its thematic mandate, as the majority of top holdings operate within the healthcare sector and focus on genetic engineering or cell therapy. However, several prominent constituents lack explicit healthcare classifications in the provided data, creating ambiguity regarding their direct contribution to genomic objectives. Notably, significant positions in companies like TWST, TEM, TXG, PSNL, GH, VCYT, NTLA, RXRX, and CMPS are marked with unavailable sector tags or non-healthcare designations, which suggests a potential dilution of the pure genomic focus compared to funds that exclusively hold classified biotech entities. This mix implies that while the portfolio leans heavily toward life sciences, it includes elements whose specific thematic relevance requires deeper scrutiny beyond simple sector labels.
Concentration analysis reveals a high degree of reliance on the top ten holdings, which collectively represent nearly 60% of the fund's assets, indicating substantial idiosyncratic risk tied to individual stock performance rather than broad sector trends. The healthcare allocation stands at over 40%, confirming that the bulk of capital is directed toward the intended theme, yet the presence of unclassified mega-cap or diversified technology names within the top tier suggests an attempt to stabilize volatility through broader market exposure. This strategy differentiates the fund from a pure-play biotech index but simultaneously introduces noise that may obscure the specific genomic revolution narrative. The sector weights appear generally consistent with a growth-oriented healthcare theme, though the inclusion of non-healthcare classified leaders in such high percentages warrants observation regarding whether these positions serve as thematic proxies or merely act as liquidity anchors for a volatile portfolio structure.
AI analysis of holdings alignment vs fund theme. Not investment advice. Updated: 2026-05-24 12:54:21.098701+00
🏢 Sector Analysis
AI GeneratedThe ARK Genomic Revolution ETF exhibits a pronounced sector concentration within Healthcare, which accounts for 40.5% of the portfolio across twelve distinct holdings. This heavy weighting suggests an investment thesis deeply anchored in biotechnology and genomic advancements rather than broad market diversification. The presence of multiple top-tier positions outside this primary sector indicates that while healthcare is the core engine, the fund manager maintains exposure to other thematic areas believed to align with disruptive innovation, though these secondary sectors lack specific identification in the provided data.
A significant concentration risk emerges from the fact that the top ten holdings collectively represent 59.4% of total assets. This level of aggregation implies a high degree of idiosyncratic risk, where portfolio performance becomes heavily dependent on the fortunes of individual companies rather than systemic sector trends. The dominance of specific names within this cluster means that adverse developments in any single major holding could disproportionately impact overall fund stability. Furthermore, the inclusion of holdings marked as "N/A" for their primary sectors alongside those explicitly labeled Healthcare hints at a factor tilt toward high-growth potential and innovation metrics over traditional industry classifications, potentially leading to elevated volatility compared to more diversified equity strategies.
Ultimately, this allocation structure reflects an aggressive approach focused on capturing rapid technological shifts within the life sciences domain. The strategy prioritizes conviction in specific disruptive narratives over risk mitigation through asset class diversification. Investors examining these figures must weigh the potential for outsized returns from successful genomic breakthroughs against the inherent instability derived from such a narrow and concentrated exposure profile.
AI-generated sector analysis from constituent-level data. Not investment advice. Updated: 2026-05-22 20:16:08.799726+00
Flow Driver Analysis
2-Step CircleWhich larger ETFs share ARKG's holdings — and mechanically drive its price through index rebalancing flows?
Approximately 100% of ARKG's weight flows through these larger ETFs
| Driver ETF | AUM | Expense | Shared Stocks | Weight Overlap |
|---|---|---|---|---|
| VHTVHT | $19B | — | 23 | 79.6% |
| ARKKARK Innovation ETF | $7B | 0.75% | 14 | 58.3% |
| VBKVBK | $40B | — | 13 | 54.2% |
| XBIXBI | $7B | — | 12 | 44.4% |
| VTWOVTWO | $15B | — | 8 | 36.2% |
80% of ARKG's portfolio by weight is also held by VHT, which commands 18× more assets under management. When VHT receives inflows, it mechanically buys these shared stocks — dragging ARKG's NAV along regardless of any thematic or sector catalyst. Combined, the top 5 overlapping ETFs control exposure to 100% ofARKG's weight.
Overlap computed from constituent-level holdings data across 5 ETFs. Price co-movement with driver ETFs is structural, not coincidental. Not investment advice.
ETF Look-Through Dashboard
Peer through the ETF wrapper to see exactly what you own. Every metric is computed from constituent-level data.
Weighted metrics calculated based on 12% of fund assets with available data.
Herfindahl-Hirschman Concentration Index
Morningstar-Style Box
Sector & Cap Explorer
ETF Fundamental Radar
Caution: 28% of fund weight scores below 4 — indicating weak profitability or deteriorating fundamentals.
Piotroski F-Score (Operational Health)
Score 0-9: Measures Profitability, Leverage, and Efficiency
Computed by rolling up individual stock Piotroski F-Scores, Altman Z-Scores, and Beneish M-Scores weighted by each constituent's allocation.
Earnings vs. Price Decomposition
ProprietaryARKG is up 60.0% over the last 12 months. The underlying weighted earnings growth of its constituents is +27.0%. The remaining +33.0% of performance is driven by multiple expansion (P/E inflation) — prices rose faster than earnings grew.
Earnings growth = weighted average YoY EPS growth of all constituents (capped at ±500% to limit outlier distortion). Based on 96% of fund weight with earnings data. Not investment advice.
Value Creation Map
ROIC vs WACCWhat percentage of ARKG's weight is allocated to companies that create economic value (ROIC > WACC) vs. destroy it?
Of ARKG's analyzed weight, 12% is invested in companies earning more than their cost of capital — genuine value creators. The remaining 88% consists of companies whose ROIC falls below their WACC, effectively destroying shareholder value with every dollar invested.
ROIC-WACC spread for 74% of fund weight with available data. Not investment advice.
Concentration Risk Monitor
ELEVATEDARKG's top holding TXG at 8.5% is above the 8% elevated-concentration threshold. The effective number of stocks is 21 vs. the actual count of 31.
Effective # of Stocks = 1 / HHI (Herfindahl-Hirschman Index). Variance share approximated as w² / Σw². Not investment advice.
Passive Crowding Score
MODERATEHow much of each constituent's market cap is structurally locked in passive ETFs — a proxy for liquidity fragility during sell-offs.
ARKG has a Passive Crowding Score of 26/100. On average, 7.8% of the market capitalization of ARKG's underlying holdings is structurally locked in passive ETF vehicles. This indicates relatively low passive crowding — the underlying stocks have ample active-market liquidity to absorb ETF-driven flows without significant price distortion.
Passive $ = Σ(ETF AUM × holding weight) across all 9 tracked ETFs. Actual passive ownership is higher (includes mutual funds, pension funds). Not investment advice.
Under the Hood — Top 15 Constituents
| # | Ticker | Company | Weight | P/E | F-Score |
|---|---|---|---|---|---|
| 1 | TXG | 10X GENOMICS INC-CLASS A | 8.53% | — | 5/9 |
| 2 | TEM | TEMPUS AI INC-CL A | 7.52% | — | 4/9 |
| 3 | TWST | TWIST BIOSCIENCE CORP | 7.44% | — | 5/9 |
| 4 | PSNL | PERSONALIS INC | 6.50% | — | 4/9 |
| 5 | CRSP | CRISPR THERAPEUTICS AG Healthcare | 6.14% | — | 2/9 |
| 6 | ABSI | ABSCI CORP Healthcare | 5.21% | — | 2/9 |
| 7 | LLY | ELI LILLY & CO Healthcare | 4.41% | 41.5x | 7/9 |
| 8 | GH | GUARDANT HEALTH INC | 4.38% | — | 5/9 |
| 9 | ILMN | ILLUMINA INC Healthcare | 4.24% | 34.6x | 7/9 |
| 10 | CDNA | CAREDX INC Healthcare | 4.19% | — | 5/9 |
| 11 | BEAM | BEAM THERAPEUTICS INC Healthcare | 4.06% | — | 3/9 |
| 12 | NTRA | NATERA INC Healthcare | 4.02% | — | 4/9 |
| 13 | VCYT | VERACYTE INC | 3.14% | 54.8x | 8/9 |
| 14 | CMPS | COMPASS PATHWAYS PLC Healthcare | 3.05% | — | — |
| 15 | RXRX | RECURSION PHARMACEUTICALS-A | 2.55% | — | 4/9 |
Historical Holdings Snapshots
Browse how ARKG’s holdings have changed across SEC filing dates. Showing top holdings per snapshot.
2026-07-19
15 holdings · 75.4% tracked weight| # | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|
| 1 | TXG | 8.53% | 3,117,941 | $138.7M |
| 2 | TEM | 7.52% | 2,280,850 | $122.2M |
| 3 | TWST | 7.44% | 1,326,278 | $121.0M |
| 4 | PSNL | 6.50% | 6,783,876 | $105.7M |
| 5 | CRSP | 6.14% | 2,054,702 | $99.8M |
| 6 | ABSI | 5.21% | 10,294,402 | $84.7M |
| 7 | LLY | 4.41% | 61,258 | $71.6M |
| 8 | GH | 4.38% | 459,269 | $71.2M |
| 9 | ILMN | 4.24% | 362,471 | $69.0M |
| 10 | CDNA | 4.19% | 1,687,190 | $68.1M |
| 11 | BEAM | 4.06% | 2,321,936 | $65.9M |
| 12 | NTRA | 4.02% | 241,927 | $65.3M |
| 13 | VCYT | 3.14% | 862,480 | $51.1M |
| 14 | CMPS | 3.05% | 3,981,601 | $49.5M |
| 15 | RXRX | 2.55% | 13,740,307 | $41.5M |
2026-07-18
15 holdings · 75.4% tracked weight| # | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|
| 1 | TXG | 8.53% | 3,117,941 | $138.7M |
| 2 | TEM | 7.52% | 2,280,850 | $122.2M |
| 3 | TWST | 7.44% | 1,326,278 | $121.0M |
| 4 | PSNL | 6.50% | 6,783,876 | $105.7M |
| 5 | CRSP | 6.14% | 2,054,702 | $99.8M |
| 6 | ABSI | 5.21% | 10,294,402 | $84.7M |
| 7 | LLY | 4.41% | 61,258 | $71.6M |
| 8 | GH | 4.38% | 459,269 | $71.2M |
| 9 | ILMN | 4.24% | 362,471 | $69.0M |
| 10 | CDNA | 4.19% | 1,687,190 | $68.1M |
| 11 | BEAM | 4.06% | 2,321,936 | $65.9M |
| 12 | NTRA | 4.02% | 241,927 | $65.3M |
| 13 | VCYT | 3.14% | 862,480 | $51.1M |
| 14 | CMPS | 3.05% | 3,981,601 | $49.5M |
| 15 | RXRX | 2.55% | 13,740,307 | $41.5M |
2026-07-17
15 holdings · 75.4% tracked weight| # | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|
| 1 | TXG | 8.53% | 3,117,941 | $138.7M |
| 2 | TEM | 7.52% | 2,280,850 | $122.2M |
| 3 | TWST | 7.44% | 1,326,278 | $121.0M |
| 4 | PSNL | 6.50% | 6,783,876 | $105.7M |
| 5 | CRSP | 6.14% | 2,054,702 | $99.8M |
| 6 | ABSI | 5.21% | 10,294,402 | $84.7M |
| 7 | LLY | 4.41% | 61,258 | $71.6M |
| 8 | GH | 4.38% | 459,269 | $71.2M |
| 9 | ILMN | 4.24% | 362,471 | $69.0M |
| 10 | CDNA | 4.19% | 1,687,190 | $68.1M |
| 11 | BEAM | 4.06% | 2,321,936 | $65.9M |
| 12 | NTRA | 4.02% | 241,927 | $65.3M |
| 13 | VCYT | 3.14% | 862,480 | $51.1M |
| 14 | CMPS | 3.05% | 3,981,601 | $49.5M |
| 15 | RXRX | 2.55% | 13,740,307 | $41.5M |
2026-07-16
15 holdings · 75.2% tracked weight| # | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|
| 1 | TXG | 8.54% | 3,071,921 | $140.5M |
| 2 | TEM | 7.82% | 2,247,190 | $128.7M |
| 3 | TWST | 7.36% | 1,308,229 | $121.2M |
| 4 | PSNL | 6.64% | 6,923,692 | $109.3M |
| 5 | CRSP | 6.32% | 2,024,378 | $104.0M |
| 6 | ABSI | 5.83% | 9,832,635 | $96.0M |
| 7 | GH | 4.48% | 452,501 | $73.7M |
| 8 | LLY | 4.24% | 60,358 | $69.8M |
| 9 | BEAM | 4.23% | 2,258,733 | $69.7M |
| 10 | ILMN | 4.06% | 357,131 | $66.8M |
| 11 | NTRA | 4.02% | 238,363 | $66.1M |
| 12 | VCYT | 3.07% | 849,760 | $50.6M |
| 13 | CDNA | 3.00% | 1,662,290 | $49.5M |
| 14 | CMPS | 2.86% | 3,532,694 | $47.0M |
| 15 | RXRX | 2.72% | 13,537,507 | $44.8M |
2026-07-15
15 holdings · 75.3% tracked weight| # | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|
| 1 | TXG | 8.57% | 3,064,251 | $140.3M |
| 2 | TEM | 8.03% | 2,241,580 | $131.5M |
| 3 | TWST | 7.44% | 1,316,545 | $121.8M |
| 4 | PSNL | 6.47% | 7,055,022 | $106.0M |
| 5 | CRSP | 6.22% | 2,019,324 | $101.9M |
| 6 | ABSI | 6.13% | 9,813,765 | $100.4M |
| 7 | GH | 4.41% | 451,373 | $72.3M |
| 8 | LLY | 4.24% | 60,208 | $69.4M |
| 9 | BEAM | 4.19% | 2,220,424 | $68.6M |
| 10 | ILMN | 4.16% | 356,241 | $68.1M |
| 11 | NTRA | 3.96% | 237,769 | $64.8M |
| 12 | CDNA | 2.93% | 1,658,140 | $48.0M |
| 13 | VCYT | 2.93% | 847,640 | $48.0M |
| 14 | CMPS | 2.87% | 3,515,965 | $47.1M |
| 15 | RXRX | 2.75% | 13,503,707 | $45.1M |
2026-07-14
15 holdings · 75.0% tracked weight| # | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|
| 1 | TXG | 7.90% | 3,071,921 | $128.3M |
| 2 | TEM | 7.74% | 2,247,190 | $125.7M |
| 3 | TWST | 7.41% | 1,332,285 | $120.4M |
| 4 | PSNL | 6.70% | 7,236,078 | $108.8M |
| 5 | CRSP | 6.31% | 2,024,378 | $102.5M |
| 6 | ABSI | 6.19% | 9,841,783 | $100.5M |
| 7 | GH | 4.41% | 452,501 | $71.7M |
| 8 | LLY | 4.39% | 60,358 | $71.3M |
| 9 | BEAM | 4.22% | 2,211,124 | $68.5M |
| 10 | ILMN | 4.18% | 357,131 | $67.9M |
| 11 | NTRA | 4.01% | 238,363 | $65.0M |
| 12 | VCYT | 3.01% | 849,760 | $48.8M |
| 13 | CDNA | 2.94% | 1,662,290 | $47.8M |
| 14 | CMPS | 2.86% | 3,524,765 | $46.5M |
| 15 | RXRX | 2.75% | 13,522,574 | $44.6M |
Source: SEC filings and fund provider disclosures. Shows last 6 snapshot dates, top 15 holdings per date by weight.
Risk Profile
Sharpe = risk-adjusted return (higher is better). Computed from 1,200+ trading days with 5% risk-free rate.
Fama-French 5-Factor Exposure
Academic factor model decomposition — what's really driving this ETF's returns.
Fama-French 5-Factor Model. Data: Kenneth French Data Library. Regression over 3 years of daily returns.
Price Chart with Moving Averages
What Drove ARKG Today?
Daily return attribution — which holdings contributed most (and least) to the fund's move.
Technical Setup
AI GeneratedThe ARKG ETF is currently trading at $28.15, a position that requires contextual analysis against its moving average envelope to gauge relative value. Without specific upper and lower band parameters or the precise location of the simple moving averages, it is impossible to definitively state whether this price point represents an extreme deviation suggesting imminent mean reversion or a stable consolidation within a normal range. In technical frameworks where prices trade near the outer boundaries of a standard deviation envelope, market participants often anticipate a pullback toward the central trendline; conversely, trading in the middle zone typically signals continued adherence to the prevailing momentum. The current figure alone does not reveal if the asset is stretched beyond historical volatility norms or comfortably situated within its established statistical bounds. Determining the probability of a mean-reversion event hinges on comparing this $28.15 level against recent average prices and the width of the surrounding channel. If the price were significantly distant from the long-term moving average, it might indicate an overextended condition where historical patterns suggest a correction toward fairness. However, if the current valuation aligns closely with the mean or resides within the inner half of the envelope, the likelihood of such a reversal diminishes as the trend may still be intact. Observers must weigh whether this specific price action reflects a temporary fluctuation around the norm or a structural shift in value relative to past performance metrics before assessing potential future movements based on statistical probability rather than directional prediction.
Underwater (Drawdown from Peak)
How far below the all-time high the price has been over time. Deeper = more pain for holders.
Rolling 60-Day Beta vs S&P 500 (VOO)
How the ETF's sensitivity to market moves changes over time. β > 1 = more volatile than the market.
Yield & Income
Sector Drift Over Time
How ARKG’s sector allocation has shifted across snapshots. Use the slider to travel through time.
Active Conviction Tracker
Shares bought and sold between the latest two data snapshots — reveals what the fund manager is actually doing.
AUM & Capital Flow Tracker
Estimated assets under management derived from SEC filings and daily price movements — tracks how the fund's value evolves over time.
Estimated AUM derived from the latest SEC N-PORT filing TNA ($1.31B) scaled by daily price changes. Filing snapshots update when new regulatory filings are published (quarterly for most funds, daily for ARK).
Explore More
Quant metrics computed deterministically from financial statements and price data. Updated: 2026-07-17.
SecuritiesDB is for informational purposes only. Not investment advice.